Home Products Antibodies Primary antibodies Secondary antibodies Tag antibodies Loading control antibodies Premium polyclonal antibodies Recombinant rabbit mAbs Mouse mAbs Phosphorylated antibodies Methylation antibodies Acetylated antibodies Biochemicals Research Areas
Service & Support Custom Services Support Promotion About Us
Sign In Sign Up

ANGPTL3 Rabbit mAb  (Cat.#:AYM30596)

A
小A Scan to ask
Host: RabbitClonality: MonoclonalReactivity: Human,Mouse,RatWBIF/ICC
Cat.# AYM30596
Target / gene ANGPTL3
Host Rabbit
Clonality Monoclonal
Reactivity Human, Mouse, Rat
Application WB, IF/ICC

Cat.#:AYM30596

SizePrice
50ul ¥1150.00 Add to cart
100ul ¥2100.00 Add to cart
  • Information

  • Application guide

  • Related products

  • Immunogen

  • Target data

  • Resources

  • Protocols

  • FAQs

Reactivity Human,Mouse,Rat
Host Rabbit
Clonality Monoclonal
Isotype IgG
Application WBIF/ICC
Dilution WB: 1:500 - 1:2000
IF/ICC: 1:50 - 1:200
Predicted MW 54kDa
Observed MW 54kDa
Format Liquid
Storage Store at -20℃. Avoid freeze / thaw cycles.
Buffer: PBS with 0.75% BSA,50% glycerol,pH7.3.
Conjugate Unconjugated
Positive HepG2,A375,Mouse lung,Mouse liver,Rat lung,Rat liver
Subcellular Secreted
Purification Affinity purification

Applications and conditions

Where to start

These starting conditions come from the recommended dilution, validation images, and general assay practice. Titrate for your sample and detection system.

WB Conditions for WB
Recommended dilution 1:500 - 1:2000
Suggested sample / positive control HepG2,A375,Mouse lung,Mouse liver,Rat lung,Rat liver
Key conditions Use a fresh lysate, incubate at the recommended dilution, and check the predicted and observed molecular weight
Expected result Expected signal or band near 54kDa
Controls Include a positive sample, a negative sample, and a secondary or isotype control
IF/ICC Conditions for IF/ICC
Recommended dilution 1:50 - 1:200
Suggested sample / positive control HepG2,A375,Mouse lung,Mouse liver,Rat lung,Rat liver
Key conditions Optimize fixation, permeabilization, and blocking, and include a secondary-only control
Expected result Expected fluorescence localization: Secreted
Controls Include a positive sample, a negative sample, and a secondary or isotype control

Related products

More associated products >>

Immunogen

Immunogen Recombinant fusion protein corresponding to Human ANGPTL3.
Sequence
View sequence
MFTIKLLLFIVPLVISSRIDQDNSSFDSLSPEPKSRFAMLDDVKILANGLLQLGHGLKDFVHKTKGQINDIFQKLNIFDQSFYDLSLQTSEIKEEEKELR

Target data

Background This gene encodes a member of a family of secreted proteins that function in angiogenesis. The encoded protein, which is expressed predominantly in the liver, is further processed into an N-terminal coiled-coil domain-containing chain and a C-terminal fibrinogen chain. The N-terminal chain is important for lipid metabolism, while the C-terminal chain may be involved in angiogenesis. Mutations in this gene cause familial hypobetalipoproteinemia type 2. [provided by RefSeq, Aug 2015]
Gene ID 27329
Gene name ANGPTL3
Swiss Q9Y5C1
Synonym ANGPTL3,ANGPTL3 Rabbit mAb,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5
Expression Expressed principally in liver. Weakly expressed in kidney. Binds to adipocytes. Increased expression and colocalization with activated ITGB3 in glomeruli of patients with nephrotic syndrome showing effaced podocyte foot processes (at protein level).
Functions Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism (PubMed:11788823, PubMed:12909640, PubMed:23661675, PubMed:25495645). Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake (By similarity). Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1 (PubMed:12097324, PubMed:19318355, PubMed:20581395). Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids (PubMed:17110602, PubMed:19028676). Can bind to adipocytes to activate lipolysis, releasing free fatty acids and glycerol (PubMed:12565906). Suppresses LPL specifically in oxidative tissues which is required to route very low density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food; the function may involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4 expression in WAT (By similarity). Contributes to lower plasma levels of low density lipoprotein (LDL)-cholesterol by a mechanism that is independent of the canonical pathway implicating APOE and LDLR. May stimulate hypothalamic LPL activity (By similarity).
Research area

Resources

Validation data

1 images

Validation images at the top of the page cover WB / IF/ICC.

References

No papers are linked yet. Contact technical support for application examples.

Ask for examples
Customer reviews

No reviews yet. After use, you can submit a review and experiment images.

Send feedback
Support

Support can help confirm the application, sample, dilution, controls, and assay conditions.

Support center
Need help with the application?

Send the catalog number, application, sample type, and assay. Support can confirm dilution, controls, and COA or lot documents.

FAQs

Listed applications: WB, IF/ICC. Use the validation images and recommended dilution as a starting point.
Send the catalog number and lot through the inquiry form. Support will help with the lot documents.
Use the recommended conditions as a starting concentration. Sample, fixation, and detection system may need a titration.

Protocols

Protocols
AYM30596